NCT02982590View on ClinicalTrials.gov

Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Left Ventricular Thrombosis
Interventions
DRUG

Apixaban 5 MG Oral Tablet [ELIQUIS]

Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.

DRUG

Warfarin Sodium

as controlled arm since warfarin is the standard therapy for LV thrombus

Trial Locations (1)

16150

Hospital Universiti Sains Malaysia, Kota Bharu

All Listed Sponsors
collaborator

Institut Jantung Negara

OTHER

lead

Universiti Sains Malaysia

OTHER

NCT02982590 - Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus | Biotech Hunter | Biotech Hunter